China National Biotec Group (CNBG), a wholly-owned affiliate of Chinese healthcare group Sinopharm, is picking up a stake in US-based aesthetic gel implant technology developer Advanced Aesthetic Technologies (AAT) to serve the largely unmet medical aesthetics market in China.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
